## Expanded Eligibility for the IMVAMUNE® MONKEYPOX VACCINE

### MONKEYPOX VACCINE PHYSICIAN REFERRAL

### PATIENT RISK ASSESSMENT AND REFERRAL FORM

**Important to Note**

- Referral form to be completed **ONLY** when vaccination administration is unable to be completed by a Physician or Specialty Program responsible for eligible patient care.
- To refer an eligible patient for Imvamune® Monkeypox vaccine, this form must be **COMPLETED IN FULL** and shared with the patient. Upon completion, this form may be shared digitally in pdf format to eligible patients.
- Patient **MUST** present the completed form at the clinic. The same completed form can be used for both doses when the patient is eligible for two doses of this vaccine.
- This form should **NOT** be sent to Toronto Public Health.

**Date:** mm/dd/yy

**Patient Name:** ____________________________

**Patient Address:** ____________________________

**Patient Health Card Number:** ____________________________

Based on the recommendation of the Chief Medical Officer of Health and health experts, Ontario is using a **single dose** of Imvamune® to limit the spread of the Monkeypox virus. **Two doses** are recommended **only** for moderately to severely immunocompromised individuals and certain research laboratory employees who receive a first dose of Imvamune® at least 28 days ago. Pregnant people are not eligible for two doses of the vaccine at this time.

**PATIENT ELIGIBILITY:**
The patient must meet both criteria listed below or are lab employees who work directly with replicating orthopoxviruses. Patients with other health conditions/criteria will not be accepted at this time - see page 2 for Ministry of Health definitions.

Please identify the relevant category below of patient eligibility for the Imvamune® Monkeypox vaccine.

- □ Moderately to severely immunocompromised (2 doses)(see definitions on page 2)
  - **AND** at least one of the following:
    - Someone who is an individual who meets the criteria below or who is a household member or a sexual partner of someone who identifies as:
      - Two-spirited, non-binary, trans- or cis- gender individuals who self-identify as belonging to the gay, bisexual and other men who have sex with men (gbMSM) community **AND** has at least one of the following:
        - Had a sexually transmitted infection (STI) in the past two months, such as chlamydia, gonorrhea, or syphilis;
        - Had two or more sexual partners in the past 21 days or may be planning to;
        - Attended a bathhouse, sex club or similar place for sexual contact within the past 21 or may be planning to, or who work/volunteer in these settings;
        - Had anonymous/casual sex in the past 21 days or may be planning to, including using online dating or hookup apps;
      - A sex worker or a sexual contact of an individual who engages in sex work or may be planning to
    - OR
  - □ Research lab employee who work directly with replicating orthopoxviruses (2 doses)

**Organization/Physician Name:** ____________________________

**has provided information regarding the risks, benefits, and timing of a first and/or second dose of the Imvamune® monkeypox vaccine and confirms the information above to be true and accurate to the best of our knowledge.**
Moderately to severely immunocompromised is defined as:

- Individuals receiving dialysis (hemodialysis or peritoneal dialysis)
- Individuals receiving active treatment\(^1\) (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Individuals with HIV with current CD4 count ≤ 200/mm\(^3\) or prior CD4 fraction ≤ 15% or detectable viral load (i.e., not suppressed)
- Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies\(^2\) (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the Canadian Immunization Guide for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive (See Table 2 of the Ministry of Health's List of Significantly Immunosuppressive Medications).

\(^1\) Active treatment includes patients who have completed treatment within 3 months. Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g., solely hormonal therapy or radiation therapy). See Ontario Health/Cancer Care Ontario’s Frequently Asked Questions for more information.

\(^2\) Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months.

Patients must bring this completed form to each appointment, along with their Ontario Health Card, or appropriate piece of identification, to their appointment.

- Monkeypox vaccine is available at three City operated clinics by walk-in or appointment:
  - Cloverdale Mall: 250 The East Mall, Etobicoke
  - Metro Hall: 214 Wellington Ave., Main Floor
  - Scarborough Clinic: 1 Eglinton Square (starting September 3, 2022)
- For more information or to book an appointment, please visit: [www.toronto.ca/Monkeypox](http://www.toronto.ca/Monkeypox)
- Call Toronto Public Health, Health Connections, Mon – Fri, 8:30 a.m. – 4:30 p.m.
  - **Telephone:** 416-338-7600  **TTY:** 416-392-0658  **Email:** PublicHealth@toronto.ca